Xenon Pharmaceuticals (Nasdaq:XENE) granted equity inducement awards to 10 new non-officer employees under Nasdaq Listing Rule 5635(c)(4). Grants, effective May 28, 2026, include 32,750 share options at an exercise price of $54.79 and 19,200 RSUs, all under Xenon’s 2025 Inducement Equity Incentive Plan.
Options vest over four years with a 10-year term; RSUs vest in four equal annual installments. Xenon is a neuroscience-focused biopharma with lead KV7 opener azetukalner in Phase 3 trials for epilepsy, MDD, and BPD, plus early-stage potassium and sodium channel programs.
Loading...
Loading translation...
AI-generated analysis. Not financial advice.
Positive
Inducement grants of 32,750 options and 19,200 RSUs to attract 10 new employees
Option exercise price set at $54.79, matching common share closing price on grant date
Structured four-year vesting for options and RSUs supports employee retention
Negative
New 51,950 equity awards add incremental share-based compensation overhang
Key Figures
New hires:10 non-officer employeesShare options granted:32,750 optionsRSUs granted:19,200 RSUs+5 more
8 metrics
New hires10 non-officer employeesEmployees receiving inducement equity grants
RSUs granted19,200 RSUsAggregate inducement restricted share units granted
Option exercise price$54.79 per shareEqual to closing price on May 28, 2026 grant date
Option vesting cliff25% at 1 yearFirst vesting on one-year anniversary of start date
Remaining option vesting1/36th monthlyRemaining options vest monthly over following three years
Option term10-year termDuration of inducement stock options
RSU vesting25% annually for 4 yearsRSUs vest on each of first four anniversaries of start date
Market Reality Check
Price:$54.73Vol:Volume 2,375,487 vs 20-da...
high vol
$54.73Last Close
VolumeVolume 2,375,487 vs 20-day average 1,159,682 (relative volume 2.05x) indicates elevated trading activity before this filing.high
TechnicalPrice at 54.79 is trading above the 200-day moving average of 45.37, indicating a pre-existing upward trend into this news.
Peers on Argus
XENE was up 1.65% while peers showed mixed moves: RARE (-0.64%), SRRK (-1.23%), ...
XENE was up 1.65% while peers showed mixed moves: RARE (-0.64%), SRRK (-1.23%), VKTX (+0.69%), IMVT (+1.52%), SLNO (+0.04%). With no peers in the momentum scanner, this points to stock-specific dynamics rather than a broad biotech move.
Participation in four Q2 2026 investor conferences to engage shareholders.
Pattern Detected
Recent history shows modest positive reactions to earnings and routine news, but a notable -4.37% drop on strong Phase 3 data, suggesting occasional sell-the-news behavior on clinical catalysts while inducement grants have coincided with mild gains.
Recent Company History
Over the last few months, Xenon has reported Q1 2026 results with positive Phase 3 X-TOLE2 topline data, cash and securities of $1.34B and runway into 2029 (news_id 1053691). It has repeatedly used inducement equity grants for new hires (news_id 1049614) under its inducement plan, alongside major clinical presentations for azetukalner in focal onset seizures (news_id 1041768) and regular investor outreach via conferences (news_id 1040110). Today’s inducement grants continue that pattern of using equity to recruit non-officer employees as late-stage programs advance.
Market Pulse Summary
This announcement details routine inducement equity grants—32,750 options and 19,200 RSUs at an exer...
Analysis
This announcement details routine inducement equity grants—32,750 options and 19,200 RSUs at an exercise price of $54.79—to 10 new non-officer employees under Nasdaq Listing Rule 5635(c)(4). The four-year vesting schedules align employee incentives with longer-term performance. In context of Xenon’s ongoing Phase 3 and Phase 1 programs and prior expansion of its inducement equity plan, investors may focus on how continued hiring supports development milestones while modestly increasing potential dilution over time.
"aggregate of 32,750 share options and 19,200 restricted share units (RSUs)."
Restricted share units (RSUs) are a promise from a company to give an employee or service provider actual shares or cash equal to the shares after certain conditions are met, typically staying with the company for a set time or hitting performance targets. Think of them like a time-locked gift card that becomes usable only after you’ve earned it. For investors, RSUs matter because they align employee incentives with company performance and can increase the number of shares outstanding over time, diluting existing ownership and affecting earnings per share.
rsusfinancial
"19,200 restricted share units (RSUs). All of the foregoing share options"
RSUs, or restricted stock units, are a form of company shares given to employees as part of their compensation. They are typically awarded with certain restrictions, such as a waiting period before they can be fully owned or sold, similar to earning a gift that becomes fully yours over time. For investors, RSUs can impact a company's stock offerings and reflect how much the company relies on stock-based incentives to attract and retain talent.
nasdaq listing rule 5635(c)(4)regulatory
"with the Company in accordance with Nasdaq Listing Rule 5635(c)(4)."
NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.
exercise pricefinancial
"The share options have an exercise price of $54.79 per common share,"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
phase 3medical
"azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials"
Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.
phase 1medical
"NaV1.7 programs in Phase 1 development for the potential treatment of pain."
Phase 1 is the first stage of testing a new drug or medical treatment in people, focused primarily on safety, how the body handles the product, and finding a tolerated dose. Think of it as a short, tightly controlled experiment with a small group to check for dangerous side effects before wider testing; for investors it is an early milestone that reduces some uncertainty but still carries high risk and potential for both big value changes and setbacks.
kv7medical
"selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment"
Kv7 denotes a family of potassium ion channels in cell membranes that act like tiny gatekeepers controlling electrical signals in nerves and muscles; drugs that open or block these channels can change how cells fire. Investors care because Kv7 is a common drug target for conditions such as epilepsy, pain and some cardiac disorders, so breakthroughs or setbacks in Kv7-focused therapies can affect clinical progress, regulatory reviews and potential market value.
nav1.7medical
"including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment"
NAV1.7 is a specific protein in nerve cells that helps transmit pain signals to the brain; think of it as a gatekeeper that opens and closes to let electrical messages through. Investors watch drugs that block or modify NAV1.7 because successful therapies could relieve chronic pain without opioids, creating large market opportunities, while clinical setbacks or safety issues can sharply affect a company's valuation.
AI-generated analysis. Not financial advice.
See more from StockTitan in Google Search and AI answers.Adds StockTitan as a preferred source · opens Google
VANCOUVER, British Columbia and BOSTON, MA, May 29, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need, today announced equity inducement grants to 10 new non-officer employees consisting of an aggregate of 32,750 share options and 19,200 restricted share units (RSUs). All of the foregoing share options and RSUs were approved by the Compensation Committee of the Company’s Board of Directors with an effective date of May 28, 2026 and were granted as inducements material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).
The share options have an exercise price of $54.79 per common share, which is equal to the closing price per share of Xenon’s common shares on the grant date of May 28, 2026. The share option grants vest over four years, with 25% vesting on the one-year anniversary of the respective employee’s start date and 1/36th of the remaining options vesting monthly thereafter on the last day of each month, subject to such option recipient’s continued service relationship with the Company. Each option has a 10-year term and is subject to the terms and conditions of the share option agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan. The RSUs will vest as to 25% of the underlying shares on each of the first four anniversaries of the respective employee’s start date, subject to such employee’s continued service relationship with the Company. Each RSU grant is subject to the terms and conditions of the restricted share unit award agreement and the terms of the Company’s Amended and Restated 2025 Inducement Equity Incentive Plan.
About Xenon Pharmaceuticals Inc. Xenon Pharmaceuticals (Nasdaq: XENE) is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics for patients in need. Xenon’s lead molecule, azetukalner, is a novel, potent, selective KV7 potassium channel opener in Phase 3 clinical trials for the treatment of epilepsy, major depressive disorder (MDD) and bipolar depression (BPD). Xenon is also advancing an early-stage portfolio of multiple promising potassium and sodium channel modulators, including KV7 and NaV1.7 programs in Phase 1 development for the potential treatment of pain. Xenon has offices in Vancouver, British Columbia, and Boston, Massachusetts. For more information, visit www.xenon-pharma.com and follow us on LinkedIn and X.
Xenon and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in the US, Canada, and elsewhere. All other trademarks belong to their respective owner.
For Media: Colleen Alabiso Senior Vice President, Corporate Affairs media@xenon-pharma.com
FAQ
What equity inducement grants did Xenon Pharmaceuticals (XENE) announce on May 29, 2026?
Xenon announced inducement grants totaling 32,750 share options and 19,200 RSUs for 10 new non-officer employees. According to Xenon, these awards were approved effective May 28, 2026 under its Amended and Restated 2025 Inducement Equity Incentive Plan.
What is the exercise price and vesting schedule for Xenon Pharmaceuticals (XENE) May 2026 inducement options?
The inducement options have a $54.79 exercise price, equal to Xenon’s May 28, 2026 closing share price. According to Xenon, 25% vest after one year, with the remaining 75% vesting monthly over three additional years, subject to continued service.
How do the May 2026 RSU inducement awards at Xenon Pharmaceuticals (XENE) vest?
The 19,200 RSUs vest in four equal annual installments tied to each employee’s start date. According to Xenon, 25% of underlying shares vest on each of the first four anniversaries, subject to the employee’s continued service relationship with the company.
Under which plan were Xenon Pharmaceuticals (XENE) May 2026 inducement grants issued?
The May 2026 inducement options and RSUs were granted under Xenon’s Amended and Restated 2025 Inducement Equity Incentive Plan. According to Xenon, each award is governed by a specific option or restricted share unit agreement aligned with this plan.
Why did Xenon Pharmaceuticals (XENE) use Nasdaq Listing Rule 5635(c)(4) for these inducement grants?
The company used Nasdaq Listing Rule 5635(c)(4) to grant equity as a material inducement to new hires. According to Xenon, these non-officer employee awards support recruitment by providing options and RSUs tied to future service and long-term company performance.
What is Xenon Pharmaceuticals’ (XENE) lead drug candidate and clinical focus mentioned with the inducement grants?
Xenon’s lead molecule, azetukalner, is a KV7 potassium channel opener in Phase 3 trials for epilepsy, MDD, and BPD. According to Xenon, it also advances early-stage KV7 and NaV1.7 programs in Phase 1 development for potential pain treatment.
